Current status and future prospects of parenteral insulin regimens, strategies and delivery systems for diabetes treatment1Abbreviations: AIA, antiinsulin antibody; CAPD, continuous ambulatory dialysis; CSII, continuous subcutaneous insulin infusion; DCCT, diabetes control complications trial; FIR, far infrared radiation; GLP1, glucagon-like peptide 1; GH, growth hormone; HbA1c, glycated hemoglobin; IDDM, insulin-dependent diabetes mellitus; IGF1, insulin-like growth factor 1; i.p., intraperitoneal; ISF, interstitial fluid; ISGIID, International Study Group on Implantable Insulin Delivery Devices; i.v., intravenous; MDI, multiple daily injections; NIDDM, non-insulin-dependent diabetes mellitus; PAI1, plasminogen activator inhibitor 1; rh IGF1, recombinant human insulin-like growth factor 1; SHBG, sex hormone binding globulin; SC, subcutaneous; SMBG, self monitoring of blood glucose; TG, triglycerides.1
作者: Nathalie Jeandidier , Sophie Boivin
DOI: 10.1016/S0169-409X(98)00072-6
关键词: Hypoglycemia 、 C-peptide 、 Amylin 、 Insulin 、 Medicine 、 Metabolic control analysis 、 Artificial pancreas 、 Diabetes mellitus 、 Intensive care medicine 、 Surgery 、 Glycemic 、 Pharmaceutical Science
摘要: … Very good acceptability is also reported in adolescents 15, 16and in elderly patients who report an easier and faster insulin injection, greater comfort and less pain, while self injecting …